Pancreatic Cancer Research

ResearcherUniversity of UtahActive in the last 2 years

Heloisa Prado Soares

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5185-2583; OpenAlex author ID A5054848065. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 7

  1. KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamanetworkopen.2024.53588↗
  2. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations … Co-author DOI 10.1158/1078-0432.ccr-22-3724↗
  3. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0676-8↗
  4. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Co-author DOI 10.1158/1535-7163.mct-14-0669↗
  5. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Co-author DOI 10.1007/s00280-014-2414-z↗
  6. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Ca… Co-author DOI 10.1371/journal.pone.0114573↗
  7. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0057289↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chris Nevala-Plagemann · 2 shared papers, 2023–2025 · strength 0.43
  2. Ignacio Garrido‐Laguna · 2 shared papers, 2023–2025 · strength 0.43
  3. Vaia Florou · 2 shared papers, 2023–2025 · strength 0.43
  4. Carter Norton · 1 shared paper, 2025 · strength 0.27
  5. Zach Rubnitz · 1 shared paper, 2025 · strength 0.27
  6. Rachna T. Shroff · 1 shared paper, 2023 · strength 0.16
  7. Kajsa E. Affolter · 1 shared paper, 2023 · strength 0.16
  8. Courtney L. Scaife · 1 shared paper, 2023 · strength 0.16
  9. Peter J. Hosein · 1 shared paper, 2023 · strength 0.16
  10. Emil Lou · 1 shared paper, 2023 · strength 0.16
  11. Wolfgang Michael Korn · 1 shared paper, 2023 · strength 0.16
  12. Enrique Rozengurt · 3 shared papers, 2013–2015 · strength 0.15
  13. Ming Ming · 2 shared papers, 2014–2015 · strength 0.10
  14. Domenico Coppola · 1 shared paper, 2019 · strength 0.10
  15. Richard D. Kim · 1 shared paper, 2019 · strength 0.10
  16. Anuhya Kommalapati · 1 shared paper, 2019 · strength 0.10
  17. Amit Mahipal · 1 shared paper, 2019 · strength 0.10
  18. James W. Sinnett‐Smith · 2 shared papers, 2013–2014 · strength 0.09
  19. Guido Eibl · 1 shared paper, 2014 · strength 0.05
  20. Krisztina Kisfalvi · 1 shared paper, 2013 · strength 0.05
  21. Jessica MacIntyre · 1 shared paper, 2014 · strength 0.04
  22. Soley Bayraktar · 1 shared paper, 2014 · strength 0.04
  23. Gilberto De Lima Lopes Jr. · 1 shared paper, 2014 · strength 0.04
  24. Caio Rocha‐Lima · 1 shared paper, 2014 · strength 0.04
  25. Jaime Rafael Merchan · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.